Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $12.9952W HIGH $25.59
Volume
1.46 M
Value Traded
20.70 M
Short % Float
25.46%
-4.71%Week
-6.55%1 Month
-25.78%3 Month
-29.94%6 Month
+10.59%5 Year
+64.66%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.51 B
EPS (TTM)
-2.47
P/E Ratio
-
Ent. Value
1.55 B
Total Shares
88.64 M
Float Shares
81.16 M
Insiders
9.12%
Institutions
115.57%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SNDX Catalyst Timeline
Dated clinical, regulatory and corporate events for Syndax Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Syndax Pharmaceuticals, Inc.
486Total events
4Upcoming
117Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 2
Event history 50
◆Poster PresentationRevumenibApprovedPresentation
Poster presentation: Revumenib as maintenance for AML following allogeneic stem cell transplantation
AML post-allogeneic stem cell transplantationsource ↗
◆Poster PresentationRevumenibApprovedPresentation
Poster presentation: Revumenib + venetoclax/azacitidine in newly diagnosed NPM1m or KMT2Ar AML ineligible for intensive chemotherapy: Trial in progress
newly diagnosed NPM1m or KMT2Ar AML ineligible for intensive chemotherapysource ↗
▲PublicationRevumenibApprovedPresentation
Publication of SAVE data in Journal of Clinical Oncology
Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AMLsource ↗
▲Oral PresentationRevumenibApprovedPresentation
Presentation of SAVE data at EHA 2026 Congress
Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AMLsource ↗
▲Oral PresentationRevumenibApprovedPresentation
Phase 2 SAVE trial of revumenib with venetoclax and decitabine/cedazuridine shows 88% ORR, 68% MRD negativity among responders, and 45% transplant rate
R/R NPM1m, KMT2Ar, or NUP98r AMLsource ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
▲Oral PresentationRevumenibApprovedPresentation
Oral presentation of post-transplant revumenib maintenance data at ASCO 2026
KMT2Ar, NPM1m, or NUP98r acute leukemiasource ↗
▲Poster PresentationRevumenibApprovedPresentation
PK assessment of revumenib: impact of food and concomitant medications at ASCO 2026
R/R acute leukemias with KMT2Ar or NPM1msource ↗
◆Poster PresentationRevumenibApprovedPresentation
Phase 3 study of revumenib plus intensive chemotherapy in newly diagnosed NPM1m AML (REVEAL-ND NPM1)
Newly diagnosed NPM1m AMLsource ↗
●AbstractRevumenibApprovedPresentation
12 Revuforj (revumenib) abstracts accepted for EHA 2026
acute leukemiasource ↗
◆Oral PresentationRevumenibApprovedPresentation
New revumenib real-world, frontline, and post-HSCT maintenance data anticipated in 2Q26
R/R NPM1m AML, KMT2Ar acute leukemia, NUP98r acute leukemiasource ↗
◆Topline ReadoutAxatilimabFiledClinical Data
Topline data from MAXPIRe Phase 2 trial of axatilimab in IPF
idiopathic pulmonary fibrosis (IPF)source ↗
◆Oral PresentationPresentation
Participation in Leerink Partners Global Healthcare Conference 2026
◆Oral PresentationPresentation
Participation at 2026 Guggenheim Emerging Outlook: Biotech Summit
●Oral PresentationAxatilimabFiledPresentation
Data presented at Tandem Meetings in February 2026
chronic GVHD-related bronchiolitis obliterans syndromesource ↗
●Oral PresentationAxatilimabFiledPresentation
Presented data from nine axatilimab abstracts at Tandem Meetings in February 2026
Chronic GVHD-related bronchiolitis obliterans syndromesource ↗
◆Oral PresentationPresentation
CEO Michael A. Metzger presents at 44th Annual J.P. Morgan Healthcare Conference
●Quarterly UpdateCorporate
Preliminary 2025 financial highlights and business updates at J.P. Morgan Healthcare Conference
▲Partnership / LicenseRevumenibApprovedCorporate
Syndax and WODA launch multi-regional managed access program for Revuforj outside the U.S.
◆Enrollment CompleteAxatilimabFiledTrial
Complete enrollment in MAXPIRe Phase 2 trial of axatilimab in IPF
idiopathic pulmonary fibrosis (IPF)source ↗
◆Oral PresentationRevumenibApprovedPresentation
Data expected at medical conference in Q1 2026
R/R metastatic MSS colorectal cancersource ↗
▲Enrollment CompleteAxatilimabFiledTrial
Completed enrollment in MAXPIRe trial in Q1 2026
Idiopathic pulmonary fibrosis (IPF)source ↗
●R&D DayPresentation
Syndax investor event to discuss key Revuforj and Niktimvo data at ASH 2025
◆Oral PresentationRevumenibApprovedPresentation
Revumenib for R/R KMT2Ar acute leukemia: outcomes by leukemia type in AUGMENT-101 oral presentation at ASH 2025
R/R KMT2Ar acute leukemiasource ↗
◆Poster PresentationRevumenibApprovedPresentation
Trial in progress: Phase I revumenib as post-transplant maintenance after allo-HCT in KMT2Ar or NPM1m acute leukemia poster at ASH 2025
KMT2Ar or NPM1m acute leukemia (post-HSCT maintenance)source ↗
◆Poster PresentationAxatilimabFiledPresentation
Phase 1b/2 axatilimab + azacitidine in advanced phase MPN, MDS/MPN overlap and high-risk CMML poster at ASH 2025
advanced phase MPN, MDS/MPN overlap, high-risk CMMLsource ↗
◆Poster PresentationRevumenibApprovedPresentation
Early real-world experience with revumenib outside clinical trial: single center retrospective review poster at ASH 2025
R/R acute leukemia (real-world)source ↗
◆Oral PresentationAxatilimabFiledPresentation
CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation oral presentation at ASH 2025
multiple myeloma (post-ASCT)source ↗
◆Poster PresentationAxatilimabFiledPresentation
Trial in progress: Phase 3 axatilimab + corticosteroids as initial treatment for moderate to severe chronic GVHD poster at ASH 2025
moderate to severe chronic GVHDsource ↗
▲Oral PresentationRevumenibApprovedPresentation
Phase 2 SAVE trial of revumenib with venetoclax and decitabine/cedazuridine in newly diagnosed AML (Abstract #47)
newly diagnosed AML (NPM1m, KMT2Ar)source ↗
◆Oral PresentationAxatilimabFiledPresentation
Safety and feasibility of 0.6 mg/kg every 4 weeks dosing of axatilimab in AGAVE-201 oral presentation at ASH 2025
chronic GVHDsource ↗
◆Poster PresentationAxatilimabFiledPresentation
Clinical and disease characteristics of initial participants in THRIVE observational study poster at ASH 2025
chronic GVHD (risk)source ↗
◆Oral PresentationPresentation
CEO Michael A. Metzger to participate in fireside chat at 8th Annual Evercore Healthcare Conference
◆Oral PresentationRevumenibApprovedPresentation
3 oral presentations at ASH 2025 Annual Meeting
acute leukemiasource ↗
◆Oral PresentationAxatilimabFiledPresentation
3 oral presentations at ASH 2025 Annual Meeting
chronic GVHDsource ↗
●Trial InitiationRevumenibApprovedTrial
REVEAL trials initiation expected by end of 2025
newly diagnosed NPM1m or KMT2Ar AMLsource ↗
●Enrollment CompleteAxatilimabFiledTrial
Enrollment completion expected by end of 2025
idiopathic pulmonary fibrosissource ↗
▲Trial InitiationRevumenibApprovedTrial
Initiated REVEAL-ND Phase 3 trial of revumenib in newly diagnosed NPM1m AML
newly diagnosed NPM1m AMLsource ↗
Past FDA Catalysts and PDUFA Decisions
How SNDX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | Revuforj (revumenib) | Phase 1/2 data presentation | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C54 / 100
Pipeline Score
$300M
Pipeline Value
$598M
Commercial Value
Overvalued
Valuation Signal
3
Drugs Scored
0.3x
rNPV / MCap
Top 13%
Micro Cap(rank 87 of 660)
Percentile Rank
Syndax Pharmaceuticals, Inc. carries a moderate pipeline score (54/100), with $750M risk-adjusted pipeline value, led by Entinostat in Non-Small Cell Lung Cancer (Phase 1), across $125B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $252.3M x 2.4 = $598M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Revuforj | $180M | $56M | +219.3% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Entinostat Small moleculeCompletedNCT02820961 | Breast Cancer | Phase 2 | COMPLETED | 280 | Jul 12, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every SNDX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Revuforj BreakthroughPriorityFast Track+1 | relapsed or refractory AML | Phase 1/2 | 2026-06-11 | 88% (37/42) ORR; 71% (30/42) CRc; 60% CR/CRh (25/42); 70% (14/20) CR/CRh in venetoclax-naïve; 50% (11/22) CR/CRh in venetoclax-exposed patients; 80% (24/30) MRD negativity among evaluable CRc responders; 45% (19/42) of patients proceeding to transplant; 63% (12/19) resuming revumenib post-transplant; 14-month median overall survival; approximately 12-month median overall survival in patients with prior venetoclax exposureRead More | Syndax Announces Publication of SAVE Data on Revuforj (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical OncologyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Metzger Michael ADirector, Officer (Chief Executive Officer) | Option | 32,375 | $0.00 | 07/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SNDX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Kynam Capital Management, LP | 9.7 % (-16.4 %) | 175.99 M | 8.05 M |
SNDX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SNDX ranks across every disease it competes in
Competitive Position is a premium feature
See how SNDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSNDX News
SNDXSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced the granting of inducement awards for stock options to nine new employees under its 2023 Inducement Plan. The awards, totaling 213,300 shares, will vest over four years, showcasing the company's strategy to attract and retain talent. Syndax continues to focus on innovative cancer therapies, including its FDA-approved products.
Read more →SNDXSyndax Announces Participation in September Investor Conferences
Syndax Pharmaceuticals announced its participation in two upcoming investor conferences in September 2026. CEO Michael A. Metzger and the management team will engage in fireside chats at the Citi Biopharma Conference and the H.C. Wainwright Global Investment Conference. Webcasts of these discussions will be accessible on the company's website.
Read more →SNDXSyndax Reports Second Quarter 2026 Financial Results and Provides Business Update
Syndax reported a strong financial performance for the second quarter of 2026, with total revenues reaching $73 million, marking a 92% increase compared to the previous year. The company's Revuforj® (revumenib) generated net revenues of $54.7 million, while Niktimvo™ (axatilimab-csfr) achieved net revenues of $60.3 million, reflecting significant year-over-year growth.
Read more →SNDXSyndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
Syndax Pharmaceuticals announced it will report its second quarter 2026 financial results on August 4, 2026. The company will also host a conference call and live audio webcast at 4:30 p.m. ET on the same day. Investors can access the webcast through the company's website, with a replay available for 90 days post-event.
Read more →SNDX▲ +5.4%on this news
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
Syndax Pharmaceuticals is set to showcase its late-stage programs and introduce new pipeline assets at an upcoming R&D event. Notably, the company is expanding its pipeline with SNDX-4321, a mutant-selective allosteric EGFR inhibitor aimed at addressing significant unmet needs in non-small cell lung cancer (NSCLC) patients. Additionally, SNDX-62122, a next-generation menin inhibitor, has been selected for development in myelofibrosis (MF) based on compelling preclinical results.
Read more →SNDXSyndax Showcases Revuforj (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Syndax Pharmaceuticals presented promising data on its menin inhibitor Revuforj (revumenib) at EHA 2026, showing significant clinical activity in various acute leukemia subtypes. Highlights include an 82% overall response rate in a real-world study and a 97% complete remission rate in newly diagnosed patients. The results suggest that revumenib may significantly improve patient outcomes, particularly in relapsed/refractory cases. The safety profile remains consistent with previous data, with no new safety concerns reported.
Read more →SNDXSyndax Announces Publication of SAVE Data on Revuforj (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
Syndax Pharmaceuticals announced promising data from the Phase 1/2 SAVE trial, showcasing high response rates for its all-oral therapy combining Revuforj, decitabine/cedazuridine, and venetoclax in treating relapsed or refractory AML patients with specific mutations. The trial demonstrated an overall response rate of 88%, with a significant portion of patients achieving minimal residual disease negativity and a robust transplant rate. The findings were published in the Journal of Clinical Oncology, indicating potential advancements in treatment standards for menin-dependent acute leukemias.
Read more →SNDXSyndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
Syndax Pharmaceuticals has announced a private placement of $250 million worth of 2.25% Convertible Senior Notes due in 2031. The net proceeds, estimated at approximately $243 million, are intended for general corporate purposes, including research and development and commercialization activities. The notes will accrue interest payable semiannually and provide a conversion option for noteholders under certain conditions. J. Wood Capital Advisors LLC is the sole placement agent for the transaction. The placement underscores Syndax's efforts to strengthen its financial position in advancing innovative cancer therapies.
Read more →SNDXSyndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax Pharmaceuticals presented promising data on Revuforj® (revumenib) at ASCO 2026, highlighting a 90% two-year overall survival rate in a cohort of 24 patients with acute leukemia who resumed treatment post-transplant. The data underscores revumenib's potential in changing treatment paradigms for relapsed/refractory acute leukemia. The company plans further studies, including a randomized trial focused on post-transplant maintenance.
Read more →SNDXSyndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
Syndax Pharmaceuticals will host an R&D Day on July 14, 2026, in New York City, featuring presentations on its late-stage programs, including revumenib and axatilimab. The event will also highlight new early-stage assets and the company's broader plans to enhance treatment options. A live webcast will be available for those unable to attend in person.
Read more →SNDXSyndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax Pharmaceuticals announced that four abstracts for Revuforj® (revumenib) have been accepted for presentation at the ASCO Annual Meeting 2026. Highlights include an oral presentation showcasing positive outcomes in patients with acute leukemia post-transplant. The data will also emphasize revumenib's unique pharmacokinetic profile and ongoing pivotal trials in combination with chemotherapy.
Read more →SNDXSyndax Announces Participation in Upcoming Investor Conferences
Syndax Pharmaceuticals has announced its participation in several upcoming investor conferences, including the TD Cowen 7th Annual Oncology Innovation Summit and the Jefferies Global Healthcare Conference. CEO Michael A. Metzger and the management team will engage in fireside chats at these events. The company aims to highlight its innovative cancer therapies and provide insights into its pipeline.
Read more →SNDXSyndax Highlights 12 Revuforj (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
Syndax Pharmaceuticals announced the acceptance of 12 abstracts on revumenib at the upcoming European Hematology Association Congress. These abstracts reveal strong activity of revumenib across various types of acute leukemia and highlight promising data from both monotherapy and combination treatments. Notably, the research includes favorable outcomes in post-transplant settings and suggests significant improvements in treatment metrics for acute myeloid leukemia. This presentation reinforces Syndax's potential leadership in menin inhibition therapies.
Read more →SNDXSyndax Reports First Quarter 2026 Financial Results and Provides Business Update
Syndax Pharmaceuticals reported its first-quarter financial results for 2026, showcasing a remarkable total revenue of $64.9 million, which aligns with a 224% year-over-year increase. The company's Revuforj (revumenib) and Niktimvo (axatilimab-csfr) generated notable net revenues of $48.9 million and $55.1 million, respectively. The report emphasizes strong adoption in specific cancer treatments and anticipates new data releases and ongoing clinical trials later in the year, positioning Syndax for continued growth and market leadership.
Read more →SNDXSyndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
Syndax Pharmaceuticals announced it will report its first quarter 2026 financial results on April 30, 2026. The company will also host a conference call and webcast to discuss the results and provide a business update. Investors can access the call through a dedicated dial-in number or via a live audio webcast.
Read more →About Syndax Pharmaceuticals, Inc.
Headquarters730 THIRD AVENUE, NEW YORK, NY, 10017
BIOPHARMAWATCH ELITE PLUS
Trade the next SNDX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime